PH284 nasal spray increased hunger in cancer cachexia patients, showing a 71% improvement in subjective hunger scores compared to baseline. The phase 2A study demonstrated PH284's safety, with no ...
Salk Institute researchers have identified a key protein that may help users of GLP-1 drugs such as Ozempic and Wegovy ...
Evaluation of End-of-Life Quality Care Between American Indian and White North Carolina Decedents Diagnosed With Lung Cancer, 2003-2020 Cachexia is a systemic wasting syndrome prevalent in patients ...
Vistagen (VTGN) announced results from an exploratory Phase 2A study of PH284 in cancer cachexia. PH284 is an investigational pherine nasal spray differentiated from all current treatments for the ...
In a recent study, researchers demonstrated that Z526, a novel dithiocarbamate-like compound, mitigates cancer-associated cachexia (CAC) both in vitro ...
Z526- a novel dithiocarbamate-like compound reverses cancer associated cachexia via mitigating NF-B signaling and oxidative ...
“We are highly encouraged by the potential of PH284 to improve the quality of life for those challenged by the debilitating impacts of cancer cachexia,” stated Shawn Singh, President and Chief ...
What Is the Best Diet for Metastatic Breast Cancer? There is no specific diet for metastatic breast cancer. However, in ...
Vistagen has reported positive outcomes from the exploratory Phase IIA trial of an investigational pherine nasal spray, PH284, for the treatment of cancer cachexia. The 'previously unreported ...
Actimed Therapeutics’ anti-catabolic and pro-anabolic transforming agent, S-pindolol benzoate receives US & European patents: London, UK Friday, February 7, 2025, 16:00 Hrs [IST ...
Dr. Yeh will oversee the continued clinical development of NGM Bio’s key programs, NGM120 for hyperemesis gravidarum and cancer cachexia, and ...
Vistagen, a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, announced positive results from an exploratory phase 2A study of PH284 in cancer ...